Applied Therapeutics is committed to advancing research into the causes of and treatment for SORD Deficiency.

In SORD Deficiency, the Aldose Reductase enzyme converts glucose to sorbitol, which then builds up in tissues causing symptoms of neuropathy.lx Our AT-007 program focuses on the targeted inhibition (or “turning off”) of Aldose Reductase. AT-007 is Applied Therapeutics’ lead investigational treatment, which could change the lives of people living with SORD Deficiency, as well as other diseases caused by Aldose Reductase.

AT-007 has the potential to be the first FDA-approved therapy for SORD Deficiency.